Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.60 |
| ▸ | CKS1B | P61024 | 1/20 | 0.52 |
| ▸ | SKP1 | P63208 | 1/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | KDM4D | Q6B0I6 | 5/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28856276 | 1.00 | GPR119 (0.60) | GPR119CKS1BSKP1SKP2PDE10A | |
| SCHEMBL28200582 | 1.00 | GPR119 (0.60) | GPR119CKS1BSKP1SKP2PDE10A | |
| SCHEMBL4954837 | 0.94 | GPR119 (0.65) | GPR119CKS1BSKP1SKP2PDE10A | |
| SCHEMBL29576568 | 0.93 | GPR119 (0.55) | GPR119CKS1BSKP1SKP2PDE10A | |
| SCHEMBL22774285 | 0.93 | GPR119 (0.55) | GPR119CKS1BSKP1SKP2PDE10A | |
| SCHEMBL22775604 | 0.93 | GPR119 (0.55) | GPR119CKS1BSKP1SKP2PDE10A | |
| SCHEMBL29576692 | 0.93 | GPR119 (0.55) | GPR119CKS1BSKP1SKP2PDE10A | |
| SCHEMBL21847896 | 0.92 | GPR119 (0.55) | GPR119CKS1BSKP1SKP2PDE10A | |
| SCHEMBL7487448 | 0.91 | GPR119 (0.52) | GPR119CKS1BSKP1SKP2PDE10A | |
| SCHEMBL23500781 | 0.87 | CKS1B (0.56) | GPR119CKS1BSKP1SKP2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105339355-B | Novel CYP17 inhibitor/antiandrogen | 奥赖恩公司 | 2018-02-27 | — | — | CN | disclosed |
| CN-105408332-B | Substituted triazolopyridines | 拜耳制药股份公司 | 2017-05-10 | — | — | CN | disclosed |
| US-20080090798-A1 | Heterocyclic Substituted Aminoazacycles Useful as Central Nervous System Agents | ABBOTT LABORATORIES (US) | 2008-04-17 | — | — | US | disclosed |
| US-7332504-B2 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LABORATORIES (US) | 2008-02-19 | — | — | US | disclosed |
| CN-1636990-A | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LAB (US) | 2005-07-13 | — | — | CN | disclosed |
| CN-1192028-C | Heterocyclic substituted amino nitrogen heterocycles as central nervous system medicaments | ABBOTT INC (US) | 2005-03-09 | — | — | CN | disclosed |
| US-20050043291-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-6833370-B1 | Selectively controlling neurotransmitter release; such as n-((3)-1-(6-chloro-3-pyridinyl)pyrrolidinyl)-n-methylamine | ABBOTT LABORATORIES | 2004-12-21 | — | — | US | disclosed |
| EP-1178982-B1 | HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS | ABBOTT LAB (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1428824-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LABORATORIES (US) | 2004-06-16 | — | — | EP | disclosed |
| CN-1361774-A | Heterocyclic substituted amino nitrogen heterocycles as central nervous system medicaments | ABBOTT INC (US) | 2002-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090798-A1 | Heterocyclic Substituted Aminoazacycles Useful as Central Nervous System Agents | GRIN3A, GAP43, GRIN3B | GPR119 468/4885CKS1B 1197/4885SKP1 1073/4885 |
| US-20050043291-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | GRIN3A, GAP43, GRIN3B | GPR119 468/4885CKS1B 1197/4885SKP1 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.